{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:39:58Z","timestamp":1793317198942,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H24-nanchitou (nan)-ippan-041"],"award-info":[{"award-number":["H24-nanchitou (nan)-ippan-041"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["7930006"],"award-info":[{"award-number":["7930006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["15K09691"],"award-info":[{"award-number":["15K09691"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17H04189"],"award-info":[{"award-number":["17H04189"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10157-018-1629-4","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T06:28:00Z","timestamp":1534746480000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["A review of clinical characteristics and genetic backgrounds in Alport syndrome"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-3137","authenticated-orcid":false,"given":"Kandai","family":"Nozu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Kanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketsugu","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Fujimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsusmi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Minamikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"issue":"5","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00005792-199909000-00005","volume":"78","author":"CE Kashtan","year":"1999","unstructured":"Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore). 1999;78(5):338\u201360.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/ki.1994.413","volume":"46","author":"K Nakanishi","year":"1994","unstructured":"Nakanishi K, Yoshikawa N, Iijima K, Kitagawa K, Nakamura H, Ito H, et al. Immunohistochemical study of alpha 1\u20135 chains of type IV collagen in hereditary nephritis. Kidney Int. 1994;46(5):1413\u201321.","journal-title":"Kidney Int"},{"key":"1629_CR3","first-page":"191884","volume":"7","author":"MN Rheault","year":"2016","unstructured":"Rheault MN, Kashtan CE. Inherited glomerular diseases. Ped Nephrol. 2016; 7 1918\u201384.","journal-title":"Ped Nephrol"},{"issue":"12","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/ndt\/gfu254","volume":"29","author":"A Mallett","year":"2014","unstructured":"Mallett A, Tang W, Clayton PA, Stevenson S, McDonald SP, Hawley CM, et al. End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand dialysis and transplant registry cases. Nephrol Dial Transplant. 2014;29(12):2277\u201386. https:\/\/doi.org\/10.1093\/ndt\/gfu254 .","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10157-014-1077-8","volume":"19","author":"M Hattori","year":"2015","unstructured":"Hattori M, Sako M, Kaneko T, Ashida A, Matsunaga A, Igarashi T, et al. End-stage renal disease in Japanese children: a nationwide survey during 2006\u20132011. Clin Exp Nephrol. 2015;19(5):933\u20138. https:\/\/doi.org\/10.1007\/s10157-014-1077-8 .","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1629_CR6","first-page":"736","volume":"57","author":"K Nakanishi","year":"2015","unstructured":"Nakanishi K, Yoshikawa N. Alport syndrome. Nihon Jinzo Gakkai Shi. 2015;57(4):736\u201342.","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"5","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ekir.2017.04.011","volume":"2","author":"T Yamamura","year":"2017","unstructured":"Yamamura T, Nozu K, Fu XJ, Nozu Y, Ye MJ, Shono A, et al. Natural history and genotype-phenotype correlation in female x-linked alport syndrome. Kidney Int Rep. 2017;2(5):850\u20135. https:\/\/doi.org\/10.1016\/j.ekir.2017.04.011 .","journal-title":"Kidney Int Rep"},{"issue":"4","key":"1629_CR8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","volume":"11","author":"JP Jais","year":"2000","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000;11(4):649\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","volume":"14","author":"JP Jais","year":"2003","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study. J Am Soc Nephrol. 2003;14(10):2603\u201310.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.10581014","volume":"10","author":"J Savige","year":"2015","unstructured":"Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol. 2015;10(4):703\u20139. https:\/\/doi.org\/10.2215\/CJN.10581014 .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/jhg.2017.28","volume":"62","author":"K Nozu","year":"2017","unstructured":"Nozu K, Minamikawa S, Yamada S, Oka M, Yanagita M, Morisada N, et al. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis. J Hum Genet. 2017;62(7):733\u20135. https:\/\/doi.org\/10.1038\/jhg.2017.28 .","journal-title":"J Hum Genet"},{"issue":"9","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00467-014-2797-4","volume":"29","author":"M Oka","year":"2014","unstructured":"Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol. 2014;29(9):1535\u201344. https:\/\/doi.org\/10.1007\/s00467-014-2797-4 .","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1681\/ASN.2012100985","volume":"24","author":"H Storey","year":"2013","unstructured":"Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA. COL4A3\/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol. 2013;24(12):1945\u201354. https:\/\/doi.org\/10.1681\/ASN.2012100985 .","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1629_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2215\/CJN.01000116","volume":"11","author":"N Kamiyoshi","year":"2016","unstructured":"Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol. 2016;11(8):1441\u20139. https:\/\/doi.org\/10.2215\/CJN.01000116 .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ki.2014.305","volume":"86","author":"AF Malone","year":"2014","unstructured":"Malone AF, Phelan PJ, Hall G, Cetincelik U, Homstad A, Alonso AS, et al. Rare hereditary COL4A3\/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int. 2014;86(6):1253\u20139. https:\/\/doi.org\/10.1038\/ki.2014.305 .","journal-title":"Kidney Int"},{"issue":"8","key":"1629_CR16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1681\/ASN.V981433","volume":"9","author":"K Nakanishi","year":"1998","unstructured":"Nakanishi K, Iijima K, Kuroda N, Inoue Y, Sado Y, Nakamura H, et al. Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome. J Am Soc Nephrol. 1998;9(8):1433\u201340.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ki.2013.479","volume":"85","author":"Y Hashimura","year":"2014","unstructured":"Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int. 2014;85(5):1208\u201313. https:\/\/doi.org\/10.1038\/ki.2013.479 .","journal-title":"Kidney Int"},{"issue":"4","key":"1629_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/sj.ki.5002365","volume":"72","author":"N de Patey-MariaudSerre","year":"2007","unstructured":"Patey-Mariaud de Serre N, Garfa M, Bessieres B, Noel LH, Knebelmann B. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int. 2007;72(4):512\u20136. https:\/\/doi.org\/10.1038\/sj.ki.5002365 .","journal-title":"Kidney Int"},{"issue":"9","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/humu.21304","volume":"31","author":"V Matejas","year":"2010","unstructured":"Matejas V, Hinkes B, Alkandari F, Al-Gazali L, Annexstad E, Aytac MB, et al. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat. 2010;31(9):992\u20131002. https:\/\/doi.org\/10.1002\/humu.21304 .","journal-title":"Hum Mutat"},{"issue":"11","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.2215\/CJN.04140414","volume":"9","author":"K Nozu","year":"2014","unstructured":"Nozu K, Vorechovsky I, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. X-linked Alport syndrome caused by splicing mutations in COL4A5. Clin J Am Soc Nephrol. 2014;9(11):1958\u201364. https:\/\/doi.org\/10.2215\/CJN.04140414 .","journal-title":"Clin J Am Soc Nephrol"},{"key":"1629_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1534-x","author":"C Nagano","year":"2018","unstructured":"Nagano C, Nozu K, Morisada N, Yazawa M, Ichikawa D, Numasawa K, et al. Detection of copy number variations by pair analysis using next-generation sequencing data in inherited kidney diseases. Clin Exp Nephrol. 2018. https:\/\/doi.org\/10.1007\/s10157-018-1534-x .","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10157-015-1197-9","volume":"20","author":"XJ Fu","year":"2016","unstructured":"Fu XJ, Nozu K, Eguchi A, Nozu Y, Morisada N, Shono A, et al. X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene. Clin Exp Nephrol. 2016;20(5):699\u2013702. https:\/\/doi.org\/10.1007\/s10157-015-1197-9 .","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","volume":"17","author":"O Gross","year":"2002","unstructured":"Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant. 2002;17(7):1218\u201327.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","volume":"21","author":"MR Bekheirnia","year":"2010","unstructured":"Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21(5):876\u201383. https:\/\/doi.org\/10.1681\/ASN.2009070784 .","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1629_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1681\/ASN.2008020198","volume":"19","author":"BR Migeon","year":"2008","unstructured":"Migeon BR. X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol. 2008;19(11):2052\u20139. https:\/\/doi.org\/10.1681\/ASN.2008020198 .","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1629_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00467-009-1370-z","volume":"25","author":"K Kaneko","year":"2010","unstructured":"Kaneko K, Tanaka S, Hasui M, Nozu K, Krol RP, Iijima K, et al. A family with X-linked benign familial hematuria. Pediatr Nephrol. 2010;25(3):545\u20138. https:\/\/doi.org\/10.1007\/s00467-009-1370-z .","journal-title":"Pediatr Nephrol"},{"key":"1629_CR27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018030228","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, et al. Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2018. https:\/\/doi.org\/10.1681\/ASN.2018030228 .","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/ndt\/gfn005","volume":"23","author":"RP Krol","year":"2008","unstructured":"Krol RP, Nozu K, Nakanishi K, Iijima K, Takeshima Y, Fu XJ, et al. Somatic mosaicism for a mutation of the COL4A5 gene is a cause of mild phenotype male Alport syndrome. Nephrol Dial Transplant. 2008;23(8):2525\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfn005 .","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1629_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ejhg.2015.113","volume":"24","author":"XJ Fu","year":"2016","unstructured":"Fu XJ, Nozu K, Kaito H, Ninchoji T, Morisada N, Nakanishi K, et al. Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome. Eur J Hum Genet. 2016;24(3):387\u201391. https:\/\/doi.org\/10.1038\/ejhg.2015.113 .","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"1629_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/(SICI)1098-1004(1998)11:6<461::AID-HUMU7>3.0.CO;2-F","volume":"11","author":"C Richard","year":"1998","unstructured":"Richard C, Tranchemontagne J, Elsliger MA, Mitchell GA, Potier M, Pshezhetsky AV. Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A\/protective protein gene. Hum Mutat. 1998;11(6):461\u20139. https:\/\/doi.org\/10.1002\/(SICI)1098-1004(1998)11:6%3C461::AID-HUMU7%3E3.0.CO;2-F .","journal-title":"Hum Mutat"},{"issue":"1","key":"1629_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ekir.2016.09.056","volume":"2","author":"SM Said","year":"2017","unstructured":"Said SM, Fidler ME, Valeri AM, McCann B, Fiedler W, Cornell LD, et al. Negative staining for COL4A5 correlates with worse prognosis and more severe ultrastructural alterations in males with Alport syndrome. Kidney Int Rep. 2017;2(1):44\u201352. https:\/\/doi.org\/10.1016\/j.ekir.2016.09.056 .","journal-title":"Kidney Int Rep"},{"issue":"5","key":"1629_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","volume":"28","author":"NJ Webb","year":"2013","unstructured":"Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol. 2013;28(5):737\u201343. https:\/\/doi.org\/10.1007\/s00467-012-2372-9 .","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"1629_CR33","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","volume":"26","author":"NJ Webb","year":"2011","unstructured":"Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, et al. Efficacy and safety of losartan in children with Alport syndrome\u2013results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. 2011;26(8):2521\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfq797 .","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1629_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81(5):494\u2013501. https:\/\/doi.org\/10.1038\/ki.2011.407 .","journal-title":"Kidney Int"},{"issue":"3","key":"1629_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","volume":"24","author":"J Savige","year":"2013","unstructured":"Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364\u201375. https:\/\/doi.org\/10.1681\/ASN.2012020148 .","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1629_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1046\/j.1523-1755.1999.0550031051.x","volume":"55","author":"L Callis","year":"1999","unstructured":"Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport\u2019s syndrome. Kidney Int. 1999;55(3):1051\u20136. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.0550031051.x .","journal-title":"Kidney Int"},{"issue":"2","key":"1629_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/BF00866293","volume":"6","author":"L Callis","year":"1992","unstructured":"Callis L, Vila A, Nieto J, Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport\u2019s syndrome. Pediatr Nephrol. 1992;6(2):140\u20134.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1629_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10157-013-0836-2","volume":"18","author":"K Sugimoto","year":"2014","unstructured":"Sugimoto K, Fujita S, Miyazawa T, Nishi H, Enya T, Izu A, et al. Cyclosporin A may cause injury to undifferentiated glomeruli persisting in patients with Alport syndrome. Clin Exp Nephrol. 2014;18(3):492\u20138. https:\/\/doi.org\/10.1007\/s10157-013-0836-2 .","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"1629_CR39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-010-1484-3","volume":"25","author":"L Massella","year":"2010","unstructured":"Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol. 2010;25(7):1269\u201375. https:\/\/doi.org\/10.1007\/s00467-010-1484-3 .","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1629_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00467-006-0227-y","volume":"22","author":"M Charbit","year":"2007","unstructured":"Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57\u201363. https:\/\/doi.org\/10.1007\/s00467-006-0227-y .","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"1629_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1399-3046.2006.00528.x","volume":"10","author":"CE Kashtan","year":"2006","unstructured":"Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant. 2006;10(6):651\u20137. https:\/\/doi.org\/10.1111\/j.1399-3046.2006.00528.x .","journal-title":"Pediatr Transplant"},{"issue":"5","key":"1629_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/scd.2015.0305","volume":"25","author":"D Moschidou","year":"2016","unstructured":"Moschidou D, Corcelli M, Hau KL, Ekwalla VJ, Behmoaras JV, De Coppi P, et al. Human chorionic stem cells: podocyte differentiation and potential for the treatment of Alport syndrome. Stem Cells Dev. 2016;25(5):395\u2013404. https:\/\/doi.org\/10.1089\/scd.2015.0305 .","journal-title":"Stem Cells Dev"},{"issue":"3","key":"1629_CR43","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1172\/JCI39569","volume":"120","author":"M Tanaka","year":"2010","unstructured":"Tanaka M, Asada M, Higashi AY, Nakamura J, Oguchi A, Tomita M, et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest. 2010;120(3):768\u201377. https:\/\/doi.org\/10.1172\/JCI39569 .","journal-title":"J Clin Invest"},{"key":"1629_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-med-120611-144851","volume":"64","author":"SW Peltz","year":"2013","unstructured":"Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med. 2013;64:407\u201325. https:\/\/doi.org\/10.1146\/annurev-med-120611-144851 .","journal-title":"Annu Rev Med"},{"key":"1629_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2015.03.008 .","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"1629_CR46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00439-017-1789-4","volume":"136","author":"N Kataoka","year":"2017","unstructured":"Kataoka N. Modulation of aberrant splicing in human RNA diseases by chemical compounds. Hum Genet. 2017;136(9):1237\u201345. https:\/\/doi.org\/10.1007\/s00439-017-1789-4 .","journal-title":"Hum Genet"},{"issue":"3","key":"1629_CR47","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1523-1755.2004.00453.x","volume":"65","author":"YY Wang","year":"2004","unstructured":"Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J. COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int. 2004;65(3):786\u201390. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00453.x .","journal-title":"Kidney Int"},{"key":"1629_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.018","author":"CE Kashtan","year":"2018","unstructured":"Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018. https:\/\/doi.org\/10.1016\/j.kint.2017.12.018 .","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1629-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1629-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1629-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T20:06:56Z","timestamp":1661803616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1629-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1629-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kazumoto Iijima has received grant support from Daiichi Sankyo Co. Ltd. He has also received consulting fees from Takeda Pharmaceutical Company and Kyowa Hakko Kirin Co. Ltd. Kandai Nozu has received lecture fees from Novartis Pharmaceuticals Corporation. Kazumoto Iijima and Kandai Nozu have filed a patent application on the development of antisense nucleotides for exon skipping therapy in Alport syndrome. The remaining authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required, as this study did not involve human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}